Arrowhead Pharmaceuticals Reports Profitable Quarter on Strong Launch, Shares Hold Steady
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) has released its financial results for the first quarter of fiscal 2026, marking a significant milestone in the company's evolution. The quarter was defined by the successful U.S. commercial launch of its first FDA-approved drug, REDEMPLO® (plozasiran), which propelled the company to a rare quarterly profit against a backdrop of heavy investment in its expansive pipeline.
Financial Performance vs. Estimates
The biotech firm reported revenue of $264.0 million for the quarter ended December 31, 2025, a staggering increase from $2.5 million in the prior-year period. This revenue primarily stemmed from collaboration and license agreements, including a significant upfront payment from Novartis. The reported figure came in slightly below the analyst consensus estimate of $275.5 million.
On the bottom line, Arrowhead reported net income attributable to the company of $30.8 million, or $0.22 per diluted share. This represents a dramatic turnaround from a net loss of $173.1 million, or ($1.39) per share, in the same quarter last year. The company's earnings per share (EPS) of $0.22 narrowly missed the analyst estimate of $0.26.
Market Reaction and Financial Health
Following the earnings release, Arrowhead's stock showed minimal movement in after-hours trading. This muted reaction suggests the market had largely anticipated the strong financial results driven by one-time collaboration payments. The company's financial position was substantially strengthened during the quarter through two concurrent public offerings that raised $930 million in gross proceeds. As of December 31, 2025, Arrowhead reported total cash resources of $916.6 million, providing a robust runway to advance its clinical programs.
Key Operational Highlights
Beyond the financials, the quarter was packed with transformative events that underscore Arrowhead's transition to a commercial-stage company with a deep pipeline:
- First Commercial Product Launch: The U.S. FDA approved and Arrowhead launched REDEMPLO for familial chylomicronemia syndrome (FCS). Early launch metrics were positive, with over 100 prescriptions received from a diverse prescriber base.
- Pipeline Expansion: The company advanced several key clinical programs:
- Initiated Phase 1/2a trials for ARO-DIMER-PA, a first-in-class dual-target (PCSK9 & APOC3) RNAi candidate for cardiovascular disease.
- Reported encouraging interim weight loss data for its obesity candidates, ARO-INHBE and ARO-ALK7.
- Dosed the first subjects in a Phase 1/2a trial for ARO-MAPT, an investigational therapy for Alzheimer's disease utilizing a new brain-penetrant delivery system.
- Strategic Partnerships and Milestones: Arrowhead closed a major collaboration with Novartis for its preclinical Parkinson's disease candidate, ARO-SNCA, receiving a $200 million upfront payment. The company also earned a $200 million milestone payment from Sarepta Therapeutics.
Outlook and Forward Estimates
The press release did not provide specific financial guidance for the coming quarters or full year. However, analyst estimates provide a benchmark for expectations. For the full fiscal year 2026, the current consensus sales estimate stands at approximately $410.3 million. For the upcoming second quarter, analysts are projecting sales of around $70.1 million.
The company's ability to meet these estimates will increasingly depend on the commercial traction of REDEMPLO and the continued progression of its late-stage pipeline, particularly plozasiran's potential expansion into the broader severe hypertriglyceridemia (SHTG) market, for which it recently received Breakthrough Therapy designation from the FDA.
Conclusion
Arrowhead Pharmaceuticals' fiscal Q1 2026 results solidify its transformation, driven by a landmark product launch and strategic deal-making that have flipped the company to profitability. While the EPS and revenue narrowly missed analyst targets, the foundational story is one of successful execution across commercial, clinical, and corporate fronts. The company's fortified balance sheet positions it to aggressively pursue its broad pipeline, which spans from cardiometabolic diseases to central nervous system disorders. Investor attention will now focus on the commercial ramp of REDEMPLO and key clinical data readouts throughout the year.
For a detailed look at historical earnings, future estimates, and analyst projections for Arrowhead Pharmaceuticals, visit the earnings and estimates page.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.